Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds
by Press Release from Outbreak News Today on (#4ZSY6)
Cocrystal Pharma, Inc., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into a license agreement with Kansas State University Research Foundation (KSURF) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections. Under the terms of the agreement, Cocrystal has ["]
The post Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds appeared first on Outbreak News Today.